IRF5 Antibody

Western Blot: IRF5 Antibody [NB100-1092] -

Western Blot: IRF5 Antibody [NB100-1092] - Overexpression of IRF5 in MCF-7 & MDA-MB-231 cells sensitizes them to DNA damage-induced growth inhibition. A. Endogenous IRF expression was analyzed by Western blot in transformed mammary epithelial cell lines. Levels of beta-actin are shown as loading controls. B. Western blot analysis of stable cell lines generated to overexpress retroviral pBIRF5. C. Cell survival was measured in MCF-7 & MDA-MB-231 pBabe cell lines by colony formation assay before & after treatment. Cells were treated with 0.1 or 1 μM Doxorubicin (Dox) or 2, 5 & 10 Gy gamma-IR. The number of colonies is plotted on the y-axis as percent of control; 100% represents the number of colonies in empty pBabe control lines. Data are expressed as mean ± SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between colonies in pBabe versus pBIRF5 cell lines after each treatment; * denotes P < 0.05, ** P < 0.001. Image collected & cropped by CiteAb from the following publication (http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3053), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: IRF5 Antibody [NB100-1092] -

Western Blot: IRF5 Antibody [NB100-1092] - Comparative analysis of IRF5 protein expression between immortalized lymphoid cell lines by immunoblot.(A) qRT-PCR analysis of IRF5 transcript expression in immortalized lymphoid cell lines. Data is presented as relative expression after normalization to beta-actin using the ∆∆Ct method. (B) Immunoblot analysis of endogenous IRF5 protein expression in immortalized cell lines. IRF5 expression was detected with the previously validated Cell Signaling antibody #3257 that is no longer available. beta-actin levels & apparent molecular weight standards are shown as loading controls & for size comparison, respectively. (C) Experimental details for the comparative analysis of alpha-IRF5 antibody specificity by immunoblot analysis. (D) Same as in (B)except lysates (T, THP-1; R, Ramos B cells; J, Jurkat T cells) were run on multiple independent blots for the analysis of antibody specificity; seven different commercially available alpha-IRF5 antibodies were evaluated. (E) Same as in (D) except antibodies were evaluated by IRF5 knockdown analysis. Ramos B cells were nucleofected with scrambled (Scr) or IRF5 (KD) siRNAs & lysates from same nucleofection run on multiple independent blots for comparative analysis. Arrows indicate detection of an appropriately sized band(s) corresponding to IRF5. Data (except in (C)) are representative of three independent experiments. Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/srep31002), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: IRF5 Antibody [NB100-1092] -

Western Blot: IRF5 Antibody [NB100-1092] - Down-regulation of IRF5 protein expression by siRNAs alters sensitivity to DNA damage. A. MCF-12A cells were incubated with transfection reagent alone (mock-transfected), control Lamin A/C siRNAs or 5 nM IRF5 siRNAs once (IRF5 siRNA1) or twice (IRF5 siRNA2), as described in the Materials & methods. Western blot analysis shows > 70% reduction of endogenous IRF5 proteins after normalization to beta-actin levels. B. Cells were exposed to 5 Gy IR or the same dose plus IFN-gamma (IR/ gamma) for 24 h. Percent of Annexin V-FITC stained positive cells is shown in the upper & lower right-hand quadrants. Representative histogram plots from three independent experiments performed in duplicate are shown. C. Same as in B, except cells were exposed to 1 μM Dox or Dox & IFN-gamma for five hours. Percent of Annexin V-FITC stained positive cells compared to control is plotted on y-axis. Data are expressed as mean ± SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between cells transfected with Lamin A/C siRNAs (12Asicon) & IRF5 siRNAs (12AsiIRF5) after each treatment; ** denotes P < 0.001. D. Cells were treated with the indicated doses of Dox or IR after siRNA transfection. Number of colonies is plotted on y-axis as percent of control. A total of 100% represents the number of colonies in control untreated 12Asicon cells. Data are expressed as mean ± SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between colonies in 12Asicon versus 12AsiIRF5 cells after each treatment; * denotes P < 0.05. Image collected & cropped by CiteAb from the following publication (http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3053), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: IRF5 Antibody [NB100-1092] -

Western Blot: IRF5 Antibody [NB100-1092] - Comparative analysis of IRF5 protein expression between immortalized lymphoid cell lines by immunoblot.(A) qRT-PCR analysis of IRF5 transcript expression in immortalized lymphoid cell lines. Data is presented as relative expression after normalization to beta-actin using the ∆∆Ct method. (B) Immunoblot analysis of endogenous IRF5 protein expression in immortalized cell lines. IRF5 expression was detected with the previously validated Cell Signaling antibody #3257 that is no longer available. beta-actin levels & apparent molecular weight standards are shown as loading controls & for size comparison, respectively. (C) Experimental details for the comparative analysis of alpha-IRF5 antibody specificity by immunoblot analysis. (D) Same as in (B)except lysates (T, THP-1; R, Ramos B cells; J, Jurkat T cells) were run on multiple independent blots for the analysis of antibody specificity; seven different commercially available alpha-IRF5 antibodies were evaluated. (E) Same as in (D) except antibodies were evaluated by IRF5 knockdown analysis. Ramos B cells were nucleofected with scrambled (Scr) or IRF5 (KD) siRNAs & lysates from same nucleofection run on multiple independent blots for comparative analysis. Arrows indicate detection of an appropriately sized band(s) corresponding to IRF5. Data (except in (C)) are representative of three independent experiments. Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/srep31002), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: IRF5 Antibody [NB100-1092] -

Western Blot: IRF5 Antibody [NB100-1092] - Overexpression of IRF5 in MCF-7 & MDA-MB-231 cells sensitizes them to DNA damage-induced growth inhibition. A. Endogenous IRF expression was analyzed by Western blot in transformed mammary epithelial cell lines. Levels of beta-actin are shown as loading controls. B. Western blot analysis of stable cell lines generated to overexpress retroviral pBIRF5. C. Cell survival was measured in MCF-7 & MDA-MB-231 pBabe cell lines by colony formation assay before & after treatment. Cells were treated with 0.1 or 1 μM Doxorubicin (Dox) or 2, 5 & 10 Gy gamma-IR. The number of colonies is plotted on the y-axis as percent of control; 100% represents the number of colonies in empty pBabe control lines. Data are expressed as mean ± SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between colonies in pBabe versus pBIRF5 cell lines after each treatment; * denotes P < 0.05, ** P < 0.001. Image collected & cropped by CiteAb from the following publication (http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3053), licensed under a CC-BY license. Not internally tested by Novus Biologicals.